# AZD6621

Source: https://onco.cc/drugs/azd6621/  
OnCo record `azd6621` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AZD6621 is an experimental T-cell engager from AstraZeneca in phase 2 trials for prostate cancer, aimed at CD3.

## Summary

AZD6621 is a T-cell engager developed by AstraZeneca. Its target is CD3 (the sponsor names STEAP2 x CD3 x CD8). The sponsor states: AZD6621 is a T-cell-engaging antibody that targets STEAP2, CD3 and CD8, designed to engage T cells against STEAP2-expressing prostate cancer cells (ACTIVATED-4-PC study). ClinicalTrials.gov describes the intervention as: A T Cell-engaging Antibody that targets STEAP2, CD3, and CD8. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in prostate cancer. The largest, NCT07192614, plans to enrol 52 participants with primary completion expected 2029-03-29. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: T-cell engager
- Mechanism: AZD6621 is a T-cell-engaging antibody that targets STEAP2, CD3 and CD8, designed to engage T cells against STEAP2-expressing prostate cancer cells (ACTIVATED-4-PC study).

## Sources

- ClinicalTrials.gov: trials of AZD6621: https://clinicaltrials.gov/search?intr=AZD6621

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- targets: [CD3](https://onco.cc/targets/cd3/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- trials: [A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Pr](https://onco.cc/trials/nct07192614/)

---
JSON: https://onco.cc/api/v1/entities/azd6621.json